Elicio Therapeutics (NASDAQ:ELTX) Releases Earnings Results, Beats Estimates By $0.11 EPS

Elicio Therapeutics (NASDAQ:ELTX) issued its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.11, FiscalAI reports.

Elicio Therapeutics Trading Up 2.9%

Shares of NASDAQ ELTX traded up $0.09 during trading hours on Thursday, reaching $3.15. The stock had a trading volume of 139,466 shares, compared to its average volume of 767,340. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 5.75. The firm has a market cap of $60.13 million, a price-to-earnings ratio of -1.31 and a beta of 1.30. The business’s fifty day moving average price is $4.87 and its two-hundred day moving average price is $8.50. Elicio Therapeutics has a 52-week low of $2.66 and a 52-week high of $16.00.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. LADENBURG THALM/SH SH started coverage on Elicio Therapeutics in a report on Thursday, June 18th. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright increased their target price on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday, June 15th. Wall Street Zen downgraded Elicio Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. Finally, JonesTrading cut shares of Elicio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 16th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $19.75.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ELTX. Quadrature Capital Ltd bought a new stake in Elicio Therapeutics during the 4th quarter valued at $137,000. Occudo Quantitative Strategies LP bought a new position in shares of Elicio Therapeutics during the 4th quarter worth $126,000. 683 Capital Management LLC purchased a new position in shares of Elicio Therapeutics during the fourth quarter valued at $449,000. Squarepoint Ops LLC purchased a new position in shares of Elicio Therapeutics during the fourth quarter valued at $133,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Elicio Therapeutics in the fourth quarter valued at about $187,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.